Caterina Passalia

Caterina Passalia

Auto-generated profile, based on publicly available information

Caterina Passalia

Internal Medicine Unit 3, Department of Hemato-Oncology, IRCCS AOU San Martino, IST, National Institute for Cancer Research, Genoa, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Tumori Journal
Verified
Journal Article
Closed access
CPCaterina Passalia
Caterina Passalia
PMPaola Minetto
Paola Minetto
EAEleonora Arboscello
Eleonora Arboscello
EBEnrico Balleari
Enrico Balleari
ABAndrea Bellodi
Andrea Bellodi
RGRiccardo Ghio
Riccardo Ghio
Rituximab is a murine/human chimeric monoclonal antibody directed against the CD20 antigen. It is widely used in combination with polychemotherapy regimens for the treatment of hematological disorders. There is no evidence of direct cardiotoxicity of the drug but a few cases of cardiovascular adverse events have been reported in the literature. We report on two patients affected by stage IV non-Hodgkin lymphoma with bone marrow infiltration and peripheral blood involvement who experienced cardiovascular accidents temporally related to rituximab infusion. In both cases the monoclonal antibody was administered in association with a polychemotherapy regimen but administration was postponed several days later in order to avoid severe cytokine release syndrome because of the high tumor burden. The first case concerns an episode of atrial fibrillation in a patient with a diagnosis of small B-cell lymphoma. The episode happened immediately after rituximab infusion. In the second case there was an episode of chest pain associated with fever and chills during rituximab infusion in a patient with a diagnosis of mantle cell lymphoma. In both cases we noticed an unusual correlation between symptom recurrence and the speed of rituximab infusion. Both patients presented several cardiovascular risk factors but preliminary cardiac function assessment excluded signs of heart dysfunction. The pathogenesis of cardiovascular events during rituximab infusion remains unclear. A key role might be played by cytokine release from B cells as a consequence of rituximab activity. Moreover, pre-existing silent cardiac damage could be co-responsible for the clinical manifestations we reported. We consider our clinical experience relevant because it raises an issue of good clinical practice: despite rituximab's good tolerability profile, patients with cardiovascular risk factors should undergo accurate cardiac assessment so that silent heart disease can be detected. If the suspicion of cardiac damage is high, more extensive cardiac assessment is recommended.

8 February 2014
Verified
Journal Article
Closed access
CPCaterina Passalia
Caterina Passalia
PMPaola Minetto
Paola Minetto
EAEleonora Arboscello
Eleonora Arboscello
EBEnrico Balleari
Enrico Balleari
ABAndrea Bellodi
Andrea Bellodi
RGRiccardo Ghio
Riccardo Ghio

9 September 2011 in Emergency Care Journal
Verified
Journal Article
Open access
PDF file
ABAndrea Bruzzone
Andrea Bruzzone
IPIrene Ponassi
Irene Ponassi
CPCaterina Passalia
Caterina Passalia
EAEleonora Arboscello
Eleonora Arboscello
RGRiccardo Ghio
Riccardo Ghio
We present the case report of an 80 years old woman with late posttraumatic (of low intensity without any immediate clinical alteration) onset of dysphnoea, chest pain and hypotension, in which bedside ultrasonography has been a very useful tool in immediate diagnostic definition (acute respiratory distress syndrome – ARDS due to multiple pulmonary contusions), considering and excluding all possible alternative diagnosis with the same clinical presentation, but also providing a “real time” evaluation of therapeutic regimen (hypovolemia versus excessive fluid embalance) and, last but not least, the chance to perform a close follow up of the ultrasonographic alterations (pleural effusion, signs of alveolar consolidation) pointed out at initial diagnosis. Moreworthly, it has been possible to identify the previous mentioned lesion before they had become evident to standard X-Ray chest evaluation.